Clinical Endoscopy

The Korean Society of Gastrointestinal Endoscopy (대한소화기내시경학회)
권호 표지
DOI QR코드

DOI QR Code

Safety of endoscopic retrograde cholangiopancreatography (ERCP) in cirrhosis compared to non-cirrhosis and effect of Child-Pugh score on post-ERCP complications: a systematic review and meta-analysis

  • Zahid Ijaz Tarar (Department of Medicine, University of Missouri School of Medicine) ;
  • Umer Farooq (Department of Medicine, Rochester General Hospital) ;
  • Mustafa Gandhi (Department of Medicine, University of Missouri School of Medicine) ;
  • Saad Saleem (Department of Medicine, Sunrise Hospital and Medical Center) ;
  • Ebubekir Daglilar (Department of Gastroenterology and Hepatology, Charleston area Medical Center, West Virginia University School of Medicine)
  • Received : 2023.01.09
  • Accepted : 2023.02.08
  • Published : 2023.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background/Aims: The safety of endoscopic retrograde cholangiopancreatography (ERCP) in hepatic cirrhosis and the impact of Child-Pugh class on post-ERCP complications need to be better studied. We investigated the post-ERCP complication rates in patients with cirrhosis compared with those without cirrhosis. Methods: We conducted a literature search of relevant databases to identify studies that reported post-ERCP complications in patients with hepatic cirrhosis. Results: Twenty-four studies comprising 28,201 patients were included. The pooled incidence of post-ERCP complications in cirrhosis was 15.5% (95% confidence interval [CI], 11.8%-19.2%; I2=96.2%), with an individual pooled incidence of pancreatitis 5.1% (95% CI, 3.1%-7.2%; I2=91.5%), bleeding 3.6% (95% CI, 2.8%-4.5%; I2=67.5%), cholangitis 2.9% (95% CI, 1.9%-3.8%; I2=83.4%), and perforation 0.3% (95% CI, 0.1%-0.5%; I2=3.7%). Patients with cirrhosis had a greater risk of post-ERCP complications (risk ratio [RR], 1.41; 95% CI, 1.16-1.71; I2=56.3%). The risk of individual odds of adverse events between cirrhosis and non-cirrhosis was as follows: pancreatitis (RR, 1.25; 95% CI, 1.06-1.48; I2=24.8%), bleeding (RR, 1.94; 95% CI, 1.59-2.37; I2=0%), cholangitis (RR, 1.15; 95% CI, 0.77-1.70; I2=12%), and perforation (RR, 1.20; 95% CI, 0.59-2.43; I2=0%). Conclusions: Cirrhosis is associated with an increased risk of post-ERCP pancreatitis, bleeding, and cholangitis.

Keywords

References

  1. Trap R, Adamsen S, Hart-Hansen O, et al. Severe and fatal complications after diagnostic and therapeutic ERCP: a prospective series of claims to insurance covering public hospitals. Endoscopy 1999;31:125-130.
  2. Adler DG, Baron TH, Davila RE, et al. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas. Gastrointest Endosc 2005;62:1-8.
  3. Alkhatib AA, Hilden K, Adler DG. Comorbidities, sphincterotomy, and balloon dilation predict post-ERCP adverse events in PSC patients: operator experience is protective. Dig Dis Sci 2011;56:3685-3688.
  4. Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007;102:1781-1788.
  5. Coelho-Prabhu N, Shah ND, Van Houten H, et al. Endoscopic retrograde cholangiopancreatography: utilisation and outcomes in a 10-year population-based cohort. BMJ Open 2013;3:e002689.
  6. Zhang J, Ye L, Zhang J, et al. MELD scores and Child-Pugh classifications predict the outcomes of ERCP in cirrhotic patients with choledocholithiasis: a retrospective cohort study. Medicine (Baltimore) 2015;94:e433.
  7. Navaneethan U, Njei B, Zhu X, et al. Safety of ERCP in patients with liver cirrhosis: a national database study. Endosc Int Open 2017;5:E303-E314.
  8. Farooq U, Tarar Z, Malik A, Amin M, Sifuentes H. How does cirrhosis impact mortality, morbidity, and resource utilization in non-variceal upper gastrointestinal bleeding? A nationwide analysis. Gastroenterol Rev/Prz Gastroenterol 2022;17.
  9. Mosko JD, Nguyen GC. Increased perioperative mortality following bariatric surgery among patients with cirrhosis. Clin Gastroenterol Hepatol 2011;9:897-901.
  10. Yang H, Mou Y, Hu B. Safety and efficacy of common endoscopic treatments in patients with decompensated liver cirrhosis. Ann Hepatol 2022;27:100689.
  11. Bernshteyn M, Hu L, Masood U, et al. Retrospective analysis of complications related to endoscopic retrograde cholangio-pancreatography in patients with cirrhosis vs patients without cirrhosis. World J Hepatol 2021;13:472-482.
  12. Hong J, Zuo W, Wang A, et al. Efficacy and safety of ERCP in patients with gastroesophageal varices. Medicine (Baltimore) 2020;99:e22051.
  13. Kundumadam S, Phatharacharukul P, Reinhart K, et al. Bleeding after elective interventional endoscopic procedures in a large cohort of patients with cirrhosis. Clin Transl Gastroenterol 2020;11:e00288.
  14. Kim JY, Lee HS, Chung MJ, et al. Bleeding complications and clinical safety of endoscopic retrograde cholangiopancreatography in patients with liver cirrhosis. Yonsei Med J 2019;60:440-445.
  15. Yoo T, Epistola R, Epistola J, et al. Evaluating the risk of adverse events with interventional endoscopic retrograde cholangiopancreatography and endoscopic ultrasound procedures in cirrhotic patients. World J Gastrointest Endosc 2019;11:523-530.
  16. Jagtap N, Nabi Z, Tandan M, et al. Is it safe to perform endoscopic retrograde cholangiopancreatography in decompensated cirrhosis? J Clin Exp Hepatol 2019;9:554-560.
  17. Leal C, Prado V, Colan J, et al. Adverse events and acute chronic liver failure in patients with cirrhosis undergoing endoscopic retrograde cholangiopancreatography: a multicenter matched-cohort study. Am J Gastroenterol 2019;114:89-97.
  18. Lee JC, Kim JS, Kim HW, et al. Outcome of endoscopic retrograde cholangiopancreatography in patients with clinically defined decompensated liver cirrhosis. J Dig Dis 2018;19:605-613.
  19. Peiseler M, Reiners D, Pinnschmidt HO, et al. Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis. PLoS One 2018;13:e0202686.
  20. Macias-Rodriguez RU, Ruiz-Margain A, Rodriguez-Garcia JL, et al. Risk factors associated with complications in cirrhotic patients undergoing endoscopic retrograde cholangio-pancreatography. Eur J Gastroenterol Hepatol 2017;29:238-243.
  21. Adler DG, Haseeb A, Francis G, et al. Efficacy and safety of therapeutic ERCP in patients with cirrhosis: a large multicenter study. Gastrointest Endosc 2016;83:353-359.
  22. Inamdar S, Berzin TM, Berkowitz J, et al. Decompensated cirrhosis may be a risk factor for adverse events in endoscopic retrograde cholangiopancreatography. Liver Int 2016;36:1457-1463.
  23. Churrango J, Doppalapudi K, Hsieh A, et al. Sa1171 Predictors of post-ERCP complications in patients with liver cirrhosis. Gastrointest Endosc 2016;83:AB240-AB241.
  24. Gill M, Yousuf SGN, Nawaz A, Nazir R. Outcomes of endoscopic retrograde cholangiopancreatography in patients with cirrhosis. J Hepatol 2016;64:S278.
  25. Li DM, Zhao J, Zhao Q, et al. Safety and efficacy of endoscopic retrograde cholangiopancreatography for common bile duct stones in liver cirrhotic patients. J Huazhong Univ Sci Technolog Med Sci 2014;34:612-615.
  26. Ma MY, Jiang GB, Wang X, Miao L, Ji GZ, Wang M. ERCP for treatment of choledocholithiasis in patients with liver cirrhosis. Shijie Huaren Xiaohua Zazhi 2013;21:3736-3741.
  27. Artifon EL, da Silveira EB, Aparicio D, et al. Management of common bile duct stones in cirrhotic patients with coagulopathy: a comparison of supra-papillary puncture and standard cannulation technique. Dig Dis Sci 2011;56:1904-1911.
  28. Park DH, Kim MH, Lee SK, et al. Endoscopic sphincterotomy vs. endoscopic papillary balloon dilation for choledocholithiasis in patients with liver cirrhosis and coagulopathy. Gastrointest Endosc 2004;60:180-185.
  29. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996;335:909-918.
  30. Prat F, Tennenbaum R, Ponsot P, et al. Endoscopic sphincterotomy in patients with liver cirrhosis. Gastrointest Endosc 1996;43(2 Pt 1):127-131.
  31. Sugiyama M, Atomi Y, Kuroda A, et al. Treatment of choledocholithiasis in patients with liver cirrhosis: surgical treatment or endoscopic sphincterotomy? Ann Surg 1993;218:68-73.
  32. Farooq U, Gondal AB, Franco D, et al. Validation of Tokyo guidelines 2018 for safety and mortality benefit from urgent ERCP in acute cholangitis across different age groups. J Hepatobiliary Pancreat Sci 2023;30:737-744.
  33. Kullman E, Borch K, Lindstrom E, et al. Bacteremia following diagnostic and therapeutic ERCP. Gastrointest Endosc 1992;38:444-449.
  34. Szary NM, Al-Kawas FH. Complications of endoscopic retrograde cholangiopancreatography: how to avoid and manage them. Gastroenterol Hepatol (N Y) 2013;9:496-504.
  35. Enns R, Eloubeidi MA, Mergener K, et al. ERCP-related perforations: risk factors and management. Endoscopy 2002;34:293-298.
  36. Fatima J, Baron TH, Topazian MD, et al. Pancreaticobiliary and duodenal perforations after periampullary endoscopic procedures: diagnosis and management. Arch Surg 2007;142:448-455.
  37. Mashiana HS, Dhaliwal AS, Sayles H, et al. Endoscopic retrograde cholangiopancreatography in cirrhosis: a systematic review and meta-analysis focused on adverse events. World J Gastrointest Endosc 2018;10:354-366.